Oncogene LIBRARY Articles of Interest

Articles of Interest

This selection of the best-published articles is arranged by topic. Choose your topic, click on the link. Review what you want to review, download what you need to file.

Be sure to contact us with your questions, comments, and feedback!

EGFr Research Studies

HER-2/neu Research Studies

MN/CAIX Research Studies

Ras p21 Research Studies

TIMP-1 Research Studies

VEGF165 Research Studies

uPA and PAI-1 Research Studies

EGFr Research Studies
1	Allen CL, Chapman CJ, Hitch A, et al. Serum EGFR and HER-2 levels in metastatic breast cancer patients receiving gefitinib therapy. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 2034
2	Hamer PJ, Jarosz DE, Leitzel K, et al. Serum EGFr and HER-2/neu Predicts Poor Survival in Metastatic Breast Cancer. AACC Annual Meeting Abstracts, 2006. Clin Chem Vol 52(6) Suppl,pg A168: Abstract No. E11
3	Muller V, Witzel I, Pantel K, et al. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res. 2006 Mar-Apr;26(2B):1479-87.
4	Souder C, Leitzel K, Ali S, et al. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer. 2006 Nov 15;107(10):2337-45.
5	Witzel I, Thomssen C, Krenkel S, et al. Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. Int J Biol Markers. 2006 Jul-Sep;21(3):131-40.
6	Ali SM, Leitzel K, Marx III JH, et al. Serial serum EGFR and decreased survival in metastatic breast cancer. AACR Meeting Abstracts, 2005. Proc Amer Assoc Cancer Res, Volume 46: Abstract No. 3143
7	Leitzel K, Souder C, Ali SM, et al. Serum EGFR/HER-2 combination predicts poor survival in metastatic breast cancer. J Clin Oncol, ASCO Annual Meeting Proceedings, 2005. Vol 23, No. 16S, Part I of II (June 1 Supplement),Abstract No. 9613
8	Gregorc V, Ceresoli GL, Floriani I, et al. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6006-12.
9	Baron AT, Cora EM, Lafky JM, et. al. Soluble Epidermal Growth Factor Receptor (sEGFR/sErbB1) as a Potential Risk, Screening, and Diagnostic Serum Biomarker of Epithelial Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2): 103-13.
10	Krocker J, Eggemann H, Elling D, et al. Randomized trial comparing dose-intense, biweekly epirubicin (E) followed by paclitaxel (P) to 3-weekly epirucibin (E) plus cyclophosphamide (C) followed by paclitaxel (P) for adjuvant therapy of nodal-positive breast cancer: Serum results of HER-2/neu, EGFR and CA27.29. ASCO Annual Meeting Proceedings, 2003. Proc Am Soc Clin Oncol 22, Abstract No. 105


HER-2/neu Research Studies
1	Bramwell VH, Doig GS, Tuck AB, et al. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat. 2009 Apr;114(3):503-11.
2	Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008 Sep 15;113(6):1294-301.
3	Ardavanisa A, Kountourakisa P, Kyriakoub F, et al. Trastuzumab plus Paclitaxel or Docetaxel in HER-2–Negative/HER-2 ECD–Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer. The Oncologist, 2008. 13:361–369.
4	Carney WP, Brown-Shimer S, Hamer PJ. Serum HER-2/neu testing can identify HER-2/neu positive patients previously classified as negative by tissue testing. American Association for Clinical Chemistry Annual Meeting Proceedings, 2008. Clin Chem Vol 54(56) Suppl, pg A130: Abstract No. C-96
5	Domingo-Domenech J, Fernandez PL, Filella X, et al Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol, 2008. 19(2):269-75
6	Esteva FJ. Can Circulating HER-2 Extracellular Domain Predict Response to Trastuzumab in HER-2–Negative Breast Cancer? The Oncologist, 2008. 13:370–372
7	Johnston S, O'Rouke L, Wang W, et al. Baseline serum extracellular domain HER2 expression in hormone receptor-positive metastatic breast cancer: correlation with known tissue HER2 status. Proceedings of the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium December, 2008: Abstract No. 3147
8	Johnston S, O'Rourke L, Wang W, et al. Correlation of tumor burden, liver and bone metastasis with serum extracellular domain HER2 expression in front-line metastatic breast cancer. Proceedings of the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium, 2008. December: Abstract No. 3146
9	Lipton A, Leitzel K, Chaudri-Ross HA, et al. Decrease in serum extracellular domain of HER2 at 4 and 8 weeks is associated with prolonged progression-free survival on lapatinib monotherapy. Proceedings of the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium, 2008. December: Abstract No. 3140
10	Maltzman J, Blackwell K, Stein S, et al. Serum HER-2/neu levels in clinical studies with lapatinib in HER-2/neu positive breast cancer. American Association for Clinical Chemistry Annual Meeting Proceedings, 2008. Clin Chem Vol 54(56) Suppl, pg A130: Abstract No. C-95
11	Moreno-Aspitia A, Dueck A, Lingle W, et al. Serum HER2 (sHER2) levels in early stage HER2 neu (+) breast cancer (HER2+BC). Results from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol 26, 2008. (May 20 suppl; abstr 529)
12	Asgeirsson KS, Agrawal A, Allen C, et al Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res, 2007. 9(6):R75
13	Mazouni C, Hall A, Broglio K, et al. Kinetics of serum HER-2/neu changes in patients with HER- 2-positive primary breast cancer after initiation of primary chemotherapy. Cancer. 2007 Feb 1;109(3):496-501.
14	Ali SM, Brault D, Brown-Shimer S, et al. Serum HER-2/neu decline predicts improved response to trastuzumab-based therapy in patients with normal and elevated baseline serum HER-2/neu levels. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 2030
15	Ali SM, Esteva FJ, Fornier M, et al. Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. J Clin Oncol, ASCO Annual Meeting Proceedings Part I, 2006. Vol 24, No. 18S (June 20 Supplement), Abstract No. 500
16	Ali SM, Esteva FJ, Fornier M, et al. Serum HER-2/neu Decline Predicts Improved Response to Trastuzumab-based Therapy (Serum HER-2/neu Study Group). Ann Oncol, ESMO Proceedings, 2006. 17 (Supplement 9): ix69 Abstract No. 1390
17	Allen CL, Chapman CJ, Hitch A, et al. Serum EGFR and HER-2 levels in metastatic breast cancer patients receiving gefitinib therapy. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 2034
18	Bramwell VHC, Doig GS, Tuck AB, et al. Serial measurement of serum extracellular domain of HER2 (ECD/HER2) has prognostic value in metastatic breast cancer. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 1005
19	Dinocca S, Blot E, Laberge-Le-Couteulx S, et al. Serum level of HER2 extra cellular domain (ECD) is a significant prognostic factor for survival in metastatic breast cancer without HER2 overexpression on primary tumor. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 1035
20	Fehm T, Lane N, Solomayer E, et al. Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 1004
21	Gomez HL, Chavez MA, Doval DC, et al. Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 1090
22	Gori S, Ludovini V, Mosconi A, et al. Prognostic value of serum HER-2 in early stage breast cancer (BC) patients. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 2035
23	Hamer PJ, Carney WP, Gaur VK, et al. Elevated serum levels of TIMP-1 and HER-2/neu in metastatic breast cancer patients (MBC) may be valuable in guiding targeted therapies. AACR Meeting Abstracts, 2006. Proc Amer Assoc Cancer Res, Volume 47: Abstract No. 3589
24	Hamer PJ, Jarosz DE, Leitzel K, et al. Serum EGFr and HER-2/neu Predicts Poor Survival in Metastatic Breast Cancer. AACC Annual Meeting Abstracts, 2006. Clin Chem Vol 52(6) Suppl,pg A168: Abstract No. E11
25	Kashiwaba M, Inaba T, Wakabayashi G, et al. Serum HER2/nue extra-cellualar domain level predicts clinical response in the patients treated with sequential trastuzumab monotherapy and combination with chemotherapy. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No.1008
26	Kong SY, Kang JH, Kwon Y, et al. Serum HER-2 concentration in patients with primary breast cancer. J Clin Pathol, 2006. 59(4):373-6
27	Kong SY, Nam BH, Lee KS, et al. Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast Cancer. Clin Chem. 2006 Jun 15
28	Mazouni C, Hall A, Anderson K, et al. An early decrease in serum HER-2/neu levels after initiation of primary chemotherapy for HER-2 positive breast cancer indicates response to treatment. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 1039
29	Muller V, Witzel I, Pantel K, et al. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res. 2006 Mar-Apr;26(2B):1479-87.
30	Okegawa T, Kinjo M, Nutahara K, et al. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol. 2006 Sep;13(9):1197-201.
31	Quaranta M, Daniele A, Coviello M, et al. c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation. Tumori. 2006 Jul-Aug;92(4):311-7.
32	Souder C, Leitzel K, Ali S, et al. Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. Cancer. 2006 Nov 15;107(10):2337-45.
33	Witzel I, Thomssen C, Krenkel S, et al. Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. Int J Biol Markers. 2006 Jul-Sep;21(3):131-40.
34	Carney WP. HER2 status is an important biomarker in guiding personalized HER2 therapy. Personalized Medicine, 2005. Vol. 2, No. 4, Pages 317-324
35	Esteva FJ, Cheli CD, Fritsche H, et al. Clinical Utility of Serum HER-2/neu in Monitoring and Prediction of Progression-free Survival in Metastatic Breast Cancer Patients Treated with Trastuzamab-based Therapies. Breast Cancer Res. 2005;7(4):R436-R443
36	Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005 Feb;16(2):234-9.
37	Lipton A, Leitzel K, Ali SM, et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer. 2005 Jul 15;104(2):257-63.
38	Salvadori B, Pinzani P, Distante V, et al. Comparison of pre- and postsurgical concentrations of blood HER-2 mRNA and HER-2 extracellular domain reflects HER-2 status in early breast cancer. Clin Chem. 2005 Jan;51(1):254-6.
39	Stemmler HJ, Stieber P, Lassig D, et al. Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab. Onkologie. 2005 Feb;28(2):95-7.
40	Bethune-Volters A, Labroquere M, Guepratte S, et al. Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. Anticancer Res. 2004 Mar-Apr;24(2C):1083-9.
41	Carney WP, Neumann R, Lipton A, et al. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer. 2004 Jun;5(2):105-16.
42	Colomer R, Llombart-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol. 2004 Feb;15(2):201-6.
43	Hudelist G, Kostler W, Czerwenka K, et al. Predicting the clinical course of breast cancer patients undergoing trastuzumab-based therapy: an outlook. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):201-10.
44	Koestler WJ, Schwab B, Singer CF, et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res. 2004 Mar 1;10(5):1618-24.
45	Koestler WJ, Steger GG, Soleiman A, et al. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res. 2004 Mar-Apr;24(2C):1127-30.
46	Lipton A, Leitzel K, Ali S. Predicting response to herceptin therapy. Clin Cancer Res. 2004 Mar 1;10(5):1559-60.
47	Lueftner D, Cheli C, Mickelson K, et al. ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer. Int J Biol Markers. 2004 Jul-Sep;19(3):175-82.
48	Lueftner D, Henschke P, Flath B, Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. Anticancer Res. 2004 Mar-Apr;24(2B):895-906.
49	Lueftner D, Henschke P, Kafka A, et al. Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing. Int J Biol Markers. 2004 Jan-Mar;19(1):1-13.
50	Mueller V, Witzel I, Luck HJ, et al. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer. Breast Cancer Res Treat. 2004 Jul;86(1):9-18.
51	Pichon MF, Hacene K, Guepratte S, et al. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. Clin Lab. 2004;50(3-4):163-70.
52	Regitnig P, Schippinger W, Lindbauer M, et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol. 2004 Aug;203(4):918-26.
53	Saghatchian M, Guepratte S, Hacene K, et al. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers. 2004 Jan-Mar;19(1):14-22.
54	Sandri MT, Johansson H, Colleoni M, et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Res. 2004 Mar-Apr;24(2C):1261-6.
55	Schippinger W, Regitnig P, Bauernhofer T, et al. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer. Oncol Rep. 2004 Jun;11(6):1331-6.


MN/CAIX Research Studies
1	Mahner S, Woelber L, Schwarz J, et al. Changes of VEGF-165 and CAIX serum concentrations during first line therapy of ovarian cancer patients. ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, 2008. Oct 30 - Nov 1. Abstract No: 140
2	Carney W Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Expert Rev Mol Diagn, 2007. 7(3), 309-319
3	Sivendran S, Leitzel K, Ali SM, et al. Elevated serum MN (carbonic anhydrase IX) levels in metastatic breast cancer patient serum. Proceedings for the American Association for Cancer Research, 2007. Abstract No. 2666


Ras p21 Research Studies
1	Nelli E, Leitzel K, Ali S, et al. Elevated serum ras levels in patients with hematologic malignancies. AACR Meeting Abstracts, 2006. Proc Amer Assoc Cancer Res, Volume 47: Abstract No. 1144
2	Nelli EM, Leitzel K, Ali SM, et al. Elevated serum ras level predicts decreased survival in patients with hematologic malignancies. J Clin Oncol, ASCO Annual Meeting Proceedings Part I, 2006. Vol 24, No. 18S (June 20 Supplement), Abstract# 6562


TIMP-1 Research Studies
1	Anyanwu U, Hou HY, Evans M, et al. Elevated pretreatment serum TIMP-1 level predicts reduced PFS and overall survival in trastuzumab-treated metastatic breast cancer patients [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR, 2009. Abstract nr 689
2	Hamer PJ, Lipton A, Leitzel K, et al. Serum TIMP-1 and HER-2/neu levels in metastatic breast cancer (MBC) treated with either letrozole or tamoxifen. Proceedings of the AACC/CSCC Annual Meeting, 2009. July 19-23; Chicago, IL. Abstract No. D-16
3	Lipton A, Leitzel K, Chaudri-Ross HA, et al. Serum TIMP-1 and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen in Metastatic Breast Cancer. J Clin Oncol. 2008 Jun 1;26(16):2653-8
4	Moreno-Aspitia A, Anderson KS, Reinholz MM, et al. Serum biomarker analysis in a phase II study of irinotecan in refractory metastatic breast cancer (MBC). Proceedings of the 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium, 2008. December: Abstract No. 6074
5	Oh WK, Leitzel K, Jacobus S, et al. Elevated plasma TIMP-1 and survival in metastatic castration-resistant prostate cancer patients. J Clin Oncol 26, 2008. (May 20 suppl; abstr 11077)
6	Vargas R, Jacobus S, Leitzel K, et al. Elevated plasma TIMP-1 levels predict reduced survival in metastatic castration-resistant prostate cancer patients [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR, 2008. Abstract Nr. 996
7	Vargas R, Leitzel K, Ali SM, et al. Elevated pretreatment serum TIMP-1 predicts shorter survival in patients advanced pancreatic cancer. ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, 2008. Oct 30 - Nov 1: Abstract No. 138
8	Carney WP, Brown-Shimer S, Pierce K, et al. Elevated levels of circulating TIMP-1 associated with cancer progression and poor clinical outcomes. Proceedings for the American Association for Cancer Research, 2007. Abstract No. 544
9	Hamer PJ, Leitzel K, Brown-Shimer S, et al. Elevated levels of TIMP-1 indicate a decreased response to letrozole and tamoxifen in metastatic breast cancer patients. American Association for Clinical Chemistry Annual Meeting Proceedings, 2007. Abstract Nr C-47
10	Leitzel K, Kantoff P, Oh WK, et al. Elevated TIMP-1 Levels in Prostate Cancer Cell Line Conditioned Medium and Hormone-Refractory Prostate Cancer Patient Plasma. Proceedings of the American Society of Clinical Oncology Prostate Cancer Symposium, 2007. Abstract No. 96
11	Lipton A, Ali SM, Leitzel K, et al. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer, 2007. 109(10):1933-9
12	Lipton A, Leitzel K, Chaudri-Ross HA, et al. Elevated serum TIMP-1/HER-2 predicts decreased response and survival in metastatic breast cancer. Breast Cancer Res Treat, 2007. 106(suppl 1):Abstract No. 2001
13	Oh WK, Leitzel K, Kantoff P, et al. Elevated plasma TIMP-1 levels predict reduced survival in metastatic hormone-refractory prostate cancer patients. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings, 2007. Part I. Vol 25, No. 18S (June 20 Supplement): Abstract Nr 5143
14	Sibley P, Hamer PJ, Leitzel K, et al. Elevated levels of TIMP-1 indicate a decreased response to letrozole and tamoxifen in metastatic breast cancer (MBC) patients. IFCC – FESCC – EUROMEDLAB 2007; Clin Chem Lab Med 2007; 45, Special Supplement, pp S341–S367, Abstract No. W092
15	Würtz SØ, Møller S, Mouridsen H, et al. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer - a prospective study. Breast Cancer Res Treat, 2007. 106(suppl 1):Abstract No. 1050
16	Carney WP, Jarosz DE, Leitzel K, et al. Elevated Plasma TIMP-1 Level Predicts Decreased Response and Survival in Metastatic Breast Cancer. American Association for Clinical Chemistry Annual Meeting Proceedings, 2006. Clin Chem Vol 52(6) Suppl, pg A168: Abstract No. E-12
17	Hamer PJ, Carney WP, Gaur VK, et al. Elevated serum levels of TIMP-1 and HER-2/neu in metastatic breast cancer patients (MBC) may be valuable in guiding targeted therapies. AACR Meeting Abstracts, 2006. Proc Amer Assoc Cancer Res, Volume 47: Abstract No. 3589
18	Lipton A, Leitzel K, Chaudri-Ross HA, et al. Elevated serum TIMP-1 level predicts decreased response to letrozole and tamoxifen in metastatic breast cancer. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 3028
19	Lipton A, Ali SM, Leitzel K, et al. Elevated plasma TIMP-1 level predicts decreased response and survival in metastatic breast cancer. Breast Cancer Res Treat, 2005. 94(suppl 1): Abstract No. 1032. NO ABSTRACT AVAILABLE TO VIEW


VEGF165 Research Studies
1	Mahner S, Woelber L, Schwarz J, et al. Changes of VEGF-165 and CAIX serum concentrations during first line therapy of ovarian cancer patients. ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer, 2008. Oct 30 - Nov 1. Abstract No: 140
2	Hamer PJ, Bradley SP, Gaur VK, et al. An isoform-specific VEGF165 ELISA and increases in serum VEGF165 in colon cancer patients. Proceedings for the American Association for Cancer Research, 2007. Abstract No. 5042
3	Elting J, Bigwood D, Brown-Shimer S, et al. Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma. AACR Meeting Abstracts, 2006. Proc Amer Assoc Cancer Res, Volume 47: Abstract No: 2909


uPA and PAI-1 Research Studies
1	Carney WP, Brown-Shimer S, Hamer PJ. Circulating levels of uPA and PAI-1 in breast cancer patients. American Association for Clinical Chemistry Annual Meeting Proceedings, 2008. Clin Chem Vol 54(56) Suppl, pg A131: Abstract No. C-98
2	Dos Santos N, Chapman J, Andrews H, et al. Urokinase plasminogen activator is a serum marker for breast cancer recurrence: a nested case-control pilot study by the National Cancer Institute of Canada. Breast Cancer Res Treat, 2006. 100(suppl 1): Abstract No. 1010
3	Hamer PJ, Marx JH, Leitzel K, et al. Circulating Levels of Urokinase-Type Plasminogen Activator (uPA) in Breast and Pancreatic Cancer Patients. AACC Annual Meeting Abstracts, 2005. Abstract No. B-8
4	Ali SM, Marx JH, Leizel K, et al. Pretreatment serum uPA and survival in patients with advanced pancreatic cancer. J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition), 2004. Vol 22, No 14S (July 15 Supplement), Abstract No. 4247
5	Hamer PJ, Goshgarian N, Smith J, et al. Plasma PAI-1 and uPA:PAI-1 Complex Levels a Predictive and Prognostic Factors in Patients with Metastatic Breast Cancer. Proc Amer Assoc Cancer Res, 2003. 44:[Abstract 6356]. NO ABSTRACT AVAILABLE TO VIEW
6	Lüftner D, Henschke P, Geppert R, et al. Differential Value of Serum Testing for HER-2/neu, EGFR, uPA and Ca 27.29 in Metastatic Breast Cancer: Implications for Efficacy Assessment and Monitoring. Proc Amer Assoc Cancer Res, 2003. 44:[Abstract 2477]. NO ABSTRACT AVAILABLE TO VIEW
7	Lüftner D, Henschke P, Geppert R, et al. Predictive information by serum testing for HER- 2/neu, EGFR, uPA and CA 27.29 in metastatic breast cancer: Serum HER-2/neu survives the multivariate analysis. ASCO Annual Meeting Proceedings, 2003. Proc Am Soc Clin Oncol 22, Abstract No. 207
8	Marx JH, Leitzel K, Ali SM, et al. Serum Urokinase-type Plasminogen Activator (uPA) in Patients with Pancreatic Cancer. Proc Amer Assoc Cancer Res, 2002. 43:[Abstract 1973]. NO ABSTRACT AVAILABLE TO VIEW

Siemens Healthcare Diagnostics

Library

Library

Articles of Interest